Clin Pharmacol Ther. 2009 Mar;85(3):241-6.

Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment.

Walker S, McAuslane N, Liberti L, Salek S.

Source

CMR International Institute for Regulatory Science, London, UK.

Abstract

Measuring the benefits and risks of medicines is the underlying theme whenever the development, review, and regulation of new medicines are discussed. Workshop participants were asked to take the first steps toward defining a framework for benefit-risk (BR) assessment. The framework identifies the essential elements that both regulators and companies should consider throughout the development, review, and postmarketing experience of new medicines in order to apply a consistent approach toward the assessment of BR balance.

PMID:: 19223879; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Congresses

MeSH Terms

Substances

Drugs, Investigational

LinkOut - more resources

Full Text Sources

Supplemental Content

Related citations

Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process. [Clin Pharmacol Ther. 2010]
Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.
Liberti L, Breckenridge A, Eichler HG, Peterson R, McAuslane N, Walker S. Clin Pharmacol Ther. 2010 Jan; 87(1):27-31.
Review Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance. [Drug Saf. 2007]
Review Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.
Shah RR. Drug Saf. 2007; 30(12):1093-110.
[Risk-benefit evaluation of medicinal products. An element of Health Technology Assessment]. [Bundesgesundheitsblatt Gesundheitsforschung...]
[Risk-benefit evaluation of medicinal products. An element of Health Technology Assessment].
Hart D. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Feb; 48(2):204-14.
Review Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development. [Curr Opin Investig Drugs. 2003]
Review Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development.
Korstanje C. Curr Opin Investig Drugs. 2003 May; 4(5):519-21.
A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis. [Pharmacoepidemiol Drug Saf. 2007]
A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
Mussen F, Salek S, Walker S. Pharmacoepidemiol Drug Saf. 2007 Jul; 16 Suppl 1:S2-S15.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Measuring benefit and balancing risk: strategies for the benefit-risk assessment...
Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment.
Clin Pharmacol Ther. 2009 Mar ;85(3):241-6.

PubMed
Donor hair follicle preservation by partial follicular unit extraction. A method...
Donor hair follicle preservation by partial follicular unit extraction. A method to optimize hair transplantation.
J Dermatolog Treat. 2010 Nov ;21(6):337-49.

PubMed
Acute effects of cigarette smoking on arterial stiffness and blood pressure in m...
Acute effects of cigarette smoking on arterial stiffness and blood pressure in male smokers with hypertension.
Am J Hypertens. 2007 Jun ;20(6):637-41.

PubMed
Metabolomic profiling to develop blood biomarkers for Parkinson's disease.
Metabolomic profiling to develop blood biomarkers for Parkinson's disease.
Brain. 2008 Feb ;131(Pt 2):389-96.

PubMed
Malaria parasitemia and systemic cytokine bias in pregnancy.
Malaria parasitemia and systemic cytokine bias in pregnancy.
Int J Gynaecol Obstet. 2007 Apr ;97(1):15-20. Epub 2007 Feb 28 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Supplemental Content

Related citations

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information